Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Anavex life sciences corp. save search
Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published: 2023-06-06 (Crawled : 12:00) - globenewswire.com
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 0.44%
H: 1.15%
C: 0.0%
life sciences trial anavex rett syndrome anavex®2-73 phase 2
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 0.4%
H: 6.32%
C: 5.24%
pdd-001 anavex phase 2 dementia anavex®2-73 parkinson conference presentation disease life science international tiona biomarkers
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s DiseaseThe Company anticipates topline data in the second half of 2022
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 0.17%
H: 3.65%
C: 2.32%
disease alzheimer phase 2 topline life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial
Published: 2021-06-28 (Crawled : 13:00) - biospace.com/
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
phase 2 correlation life science trial anavex®2-73 anavex biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published: 2021-06-28 (Crawled : 12:00) - anavex.com
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 20.0%
H: 6.06%
C: -2.83%
disease treatment phase 2 dementia correlation parkinson life science trial anavex®2-73 anavex biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 8.67%
H: 15.75%
C: 4.61%
treatment phase 2 life science trial anavex®2-73 anavex syndros biomarkers rett syndrome
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 4.51%
H: 0.41%
C: -0.46%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex enroll alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
Published: 2021-04-12 (Crawled : 12:00) - anavex.com
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: -0.07%
H: 1.17%
C: -8.85%
phase 2 phase 2/3 results life science trial anavex®2-73 anavex syndros rett syndrome
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
Published: 2021-03-31 (Crawled : 12:00) - anavex.com
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 1.92%
H: 7.76%
C: 4.55%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 0.0%
H: 9.26%
C: 7.27%
life science phase 2 anavex®2-73 anavex syndros rett syndrome
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2020-12-15 (Crawled : 12:01) - globenewswire.com
AVXL | $4.07 -1.21% -1.35% 130
|
Health Technology
|
| O: 20.42%
H: 2.08%
C: -4.16%
life science trial phase 2 anavex®2-73 anavex syndros rett syndrome
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
HOLO | $2.24 -5.49% 27.74% 7.7M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VIAO | $0.262 0.77% 16.03% 14M
|
Electronic Technology
DXF | $0.2708 -5.71% 14.48% 190K
|
Finance
SYTA | $2.9 17.89% 12.77% 300K
|
Non-Energy Minerals
GRFX | $0.2159 -10.04% 12.55% 5.9K
|
n/a
BHIL | $0.1722 -3.8% 12.08% 290K
|
Agriculture, Forestry, Fishing ...
ANVS | $8.99 -10.81% 10.9% 270K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.